Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 10/2017

01-10-2017 | Original paper

Treatment selection in oropharyngeal cancer: a surveillance, epidemiology, and end results (SEER) patterns of care analysis

Authors: Nitin A. Pagedar, Catherine Chioreso, Jennifer A. Schlichting, Charles F. Lynch, Mary E. Charlton

Published in: Cancer Causes & Control | Issue 10/2017

Login to get access

Abstract

Purpose

Treatment for oropharyngeal cancer (OPC) has changed over the past two decades under multiple influences. We provide a population-based description of the application of radiotherapy, surgery, and chemotherapy to OPC in 1997, 2004, and 2009.

Methods

The National Cancer Institute’s Patterns of Care study for OPC included multiple variables not available in the public-use dataset. We identified factors correlating with selection of primary surgery versus radiotherapy with or without chemotherapy (RTC) and analyzed predictors of all-cause mortality. We estimated the frequency of human papillomavirus (HPV) testing.

Results

RTC was more common in 2009 than in 1997, and was more commonly applied to Stage IV cases. However, RTC was not an independent risk factor for mortality compared with surgery. HPV status was known in 14% of patients in 2009.

Conclusions

RTC is the most common treatment for OPC, but it may not provide the best outcomes. HPV testing was uncommon in 2009.
Literature
1.
Bagnardi V, Blangiardo M, La Vecchia C, Corrao G (2001) Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health 25:263–270PubMed
2.
Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biorklund A, Rutqvist LE (1998) Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer 82:1367–1375CrossRefPubMed
3.
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294–4301CrossRefPubMedPubMedCentral
4.
Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, Reichman ME, Wu X, Chaturvedi AK, Kawaoka K (2008) Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 113:2901–2909CrossRefPubMed
5.
Weber RS, Gidley P, Morrison WH, Peters LJ, Hankins P, Wolf P, Guillamondegui O (1990) Treatment selection for carcinoma of the base of the tongue. Am J Surg 160:415–419CrossRefPubMed
6.
Allal AS, Nicoucar K, Mach N, Dulguerov P (2003) Quality of life in patients with oropharynx carcinomas: Assessment after accelerated radiotherapy with or without chemotherapy versus radical surgery and postoperative radiotherapy. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 25:833–839CrossRef
7.
Zhen WN, Karnell LH, Hoffman HT, Funk GF, Buatti JM, Menck HR (2004) The national cancer data base report on squamous cell carcinoma of the base of tongue. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 26:660–674CrossRef
8.
Chera BS, Amdur RJ, Hinerman RW, Morris CG, Villaret DB, Werning JW, Mendenhall WM (2008) Definitive radiation therapy for squamous cell carcinoma of the soft palate. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 30:1114–1119CrossRef
9.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G (2004) Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69–76CrossRefPubMed
10.
Pederson AW, Haraf DJ, Witt ME, Stenson KM, Vokes EE, Blair EA, Salama JK (2010) Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. Head Neck 32:1519–1527CrossRefPubMed
11.
Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, Sanguineti G, Jones CU, Bosch WR, Ang KK (2010) Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 76:1333–1338CrossRefPubMed
12.
Liederbach E, Lewis CM, Yao K, Brockstein BE, Wang CH, Lutfi W, Bhayani MK (2015) A Contemporary Analysis of Surgical Trends in the Treatment of Squamous Cell Carcinoma of the Oropharynx from 1998 to 2012: A Report from the National Cancer Database. Ann Surg Oncol 22:4422–4431CrossRefPubMed
13.
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF: Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40:IV-3-18
14.
Greene FL, American Joint Committee on Cancer., American Cancer Society.: AJCC cancer staging manual. 6th edn. New York: Springer-Verlag; 2002
15.
16.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
17.
Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, Har-El G, Lucente FE (1997) Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope 107:1469–1475CrossRefPubMed
18.
Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798–1804CrossRefPubMed
19.
Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081–2086CrossRefPubMed
20.
Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TPU, Iro H, Popella C, Schalhorn A (1998) Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16:1318–1324CrossRefPubMed
21.
Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98CrossRefPubMed
22.
Forastiere AA, Trotti A (1999) Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 91:2065–2066CrossRefPubMed
23.
Goldenberg D, Mackley H, Koch W, Bann DV, Schaefer EW, Hollenbeak CS (2014) Age and stage as determinants of treatment for oral cavity and oropharyngeal cancers in the elderly. Oral Oncol 50:976–982CrossRefPubMedPubMedCentral
24.
Chen AY, Schrag N, Hao YP, Stewart A, Ward E (2007) Changes in treatment of advanced oropharyngeal cancer, 1985–2001. Laryngoscope 117:16–21CrossRefPubMed
25.
VanderWalde NA, Meyer AM, Liu H, Tyree SD, Zullig LL, Carpenter WR, Shores CD, Weissler MC, Hayes DN, Fleming M, Chera BS (2013) Patterns of care in older patients with squamous cell carcinoma of the head and neck: a surveillance, epidemiology, and end results-medicare analysis. J Geriatr Oncol 4:262–270CrossRefPubMedPubMedCentral
26.
Borggreven PA, Kuik DJ, Langendijk JA, Doornaert P, de Bree R, Leemans CR (2005) Severe comorbidity negatively influences prognosis in patients with oral and oropharyngeal cancer after surgical treatment with microvascular reconstruction. Oral Oncol 41:358–364CrossRefPubMed
27.
de Cassia Braga Ribeiro K, Kowalski LP, Latorre MR (2003) Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 129:219–228CrossRefPubMed
28.
Steiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M (2003) Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 129:36–43CrossRefPubMed
29.
Zenga J, Wilson M, Adkins DR, Gay HA, Haughey BH, Kallogjeri D, Michel LS, Paniello RC, Rich JT, Thorstad WL, Nussenbaum B (2015) Treatment outcomes for T4 Oropharyngeal squamous cell carcinoma. Jama Otolaryngol Head and Neck Surg 141:1118–1127CrossRef
30.
Zevallos JP, Mitra N, Swisher-McClure S (2016) Patterns of care and perioperative outcomes in transoral endoscopic surgery for oropharyngeal squamous cell carcinoma. Head Neck 38:402–409CrossRefPubMed
31.
D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML (2007) Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956CrossRefPubMed
32.
Polednak AP, Phillips C (2014) Surveillance of the frequency and results of testing of incident oropharyngeal cancers for human papillomavirus: the potential role of population-based cancer registries. J Regist Manag 41:113–119
Metadata
Title
Treatment selection in oropharyngeal cancer: a surveillance, epidemiology, and end results (SEER) patterns of care analysis
Authors
Nitin A. Pagedar
Catherine Chioreso
Jennifer A. Schlichting
Charles F. Lynch
Mary E. Charlton
Publication date
01-10-2017
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 10/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0938-3

Other articles of this Issue 10/2017

Cancer Causes & Control 10/2017 Go to the issue

Original paper

Comparing perceived effectiveness of FDA-proposed cigarette packaging graphic health warnings between sexual and gender minorities and heterosexual adults

Original paper

Risk of depression, anxiety, and adjustment disorders in women with a suspected but unconfirmed diagnosis of breast or genital organ cancer in Germany

Original paper

A qualitative investigation among men who have sex with men on the acceptability of performing a self- or partner anal exam to screen for anal cancer

Original paper

Cancer in First Nations people living in British Columbia, Canada: an analysis of incidence and survival from 1993 to 2010

Original paper

Endometriosis and the risk of skin cancer: a prospective cohort study

Original paper

Cardiovascular disease mortality among women with endometrial cancer in the Iowa Women’s Health Study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits